Arjo AB (publ)
STO:ARJO B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Arjo AB (publ)
STO:ARJO B
|
SE |
|
R
|
Ram Ratna Wires Ltd
NSE:RAMRAT
|
IN |
|
Poonawalla Fincorp Ltd
NSE:POONAWALLA
|
IN |
Arjo AB (publ)
Arjo AB engages in the provision of medical devices and solutions. The company is headquartered in Malmo, Skane and currently employs 6,350 full-time employees. The company went IPO on 2017-12-12. The Company’s offering includes products and solutions within the product segments Patient handling, Hygiene, Disinfection, Therapeutic surfaces, Venous Thromboembolism (VTE) prevention and Diagnostics. Additionally, the Company is offering its customers complementing services. The products comprise ceiling lifts, standing and raising aids, slings, floor lifters, among others. Arjo AB (publ) operates in more than 60 countries, which the Company divides into three geographical areas: North America, Western Europe and Rest of the World.
Arjo AB engages in the provision of medical devices and solutions. The company is headquartered in Malmo, Skane and currently employs 6,350 full-time employees. The company went IPO on 2017-12-12. The Company’s offering includes products and solutions within the product segments Patient handling, Hygiene, Disinfection, Therapeutic surfaces, Venous Thromboembolism (VTE) prevention and Diagnostics. Additionally, the Company is offering its customers complementing services. The products comprise ceiling lifts, standing and raising aids, slings, floor lifters, among others. Arjo AB (publ) operates in more than 60 countries, which the Company divides into three geographical areas: North America, Western Europe and Rest of the World.
Organic Growth: Arjo delivered 3.4% organic net sales growth in Q1, with stronger order intake suggesting momentum for the rest of 2025.
Profitability Pressures: Adjusted EBITDA declined to SEK 486 million from SEK 502 million last year due to significant currency headwinds, though underlying business improved by about 6% when neutralizing for FX.
Margins: Gross margin improved slightly to 43.7% versus 43.5% a year ago, supported by lower material costs and price adjustments, partly offset by higher salary costs and FX pressure.
Cash Flow: Operating cash flow declined to SEK 184 million and cash conversion was 41%, reflecting normal Q1 seasonality and inventory build-up.
2025 Outlook: Management reaffirmed guidance for organic net sales growth within the 3–5% target range and maintained the full-year cash conversion goal of 80%. Outlook remains unchanged.
Cost Controls: Operating expenses grew by just over 4% organically, mainly from salary increases; management aims to improve OpEx to sales ratio starting in Q2 and accelerate cost reductions.
Product Launches: Two major products launched in 2025 so far, with Maxi Move 5 introduced in Q1 and another launch planned for the second half.
Tariff & FX Risks: U.S. tariff exposure is being addressed via price increases and manufacturing adjustments; FX headwinds had a major short-term impact but may not repeat if rates stabilize.
